Neuland Laboratories Limited has informed the Exchange about General Updates
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The U.S. FDA has issued an Establishment Inspection Report (EIR) and closed its inspection at Neuland Laboratories' Unit 2 manufacturing facility in Pashamylaram, Sangareddy District. The inspection was conducted from April 28, 2025 to May 2, 2025. The 'closed' status indicates the FDA found no outstanding compliance issues requiring further regulatory action. This follows the company's earlier intimation dated May 2, 2025 about the inspection.
This is a positive development for shareholders, as a closed FDA inspection removes regulatory uncertainty and supports uninterrupted exports from this facility to the U.S. market.